The rise of NP/PA influence is not a passing trend; it is a structural realignment of US healthcare. These clinicians are the ...
Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...
The FDA has delivered a Commissioner's National Priority Voucher (CNPV) to Johnson & Johnson for a combination regimen based ...
The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s ...
Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a ...
Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...
The latest judgment follows another setback in its defence in October, when a California jury awarded an eye-watering $966 ...
Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional. It will separate teams that keep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback